![]() |
|
|
Vol. 283, Issue 2, 541-547, 1997
Department of Pharmacology (M.F., P.D.), University of Padova,
Padova, Italy;
Institute of Pharmacology (P.A.B., S.G.), University of
Ferrara, Ferrara, Italy;
Institute of Pharmaceutical Sciences (L.M.,
P.F.), University of Genova, Genova, Italy
In electrically driven left atria isolated from guinea pig and rat, a
new milrinone analog, 6-ethyl-5-propionyl-1,2-dihydro-2-oxo-3-pyridine carbonitrile, produced a positive inotropic effect that was not dependent on adrenergic mechanisms and was more marked than that exerted by the parent compound. Its inotropic action was almost completely abolished by pretreatment of atria with adenosine deaminase and correlated well with its binding ability to the cardiac adenosine A1 receptor. In this regard, the analog showed a 100-fold
higher affinity for adenosine receptor than that of milrinone.
Moreover, it shifted to the right the concentration-response curves for the negative inotropic action of the stable adenosine receptor agonist
R-phenylisopropyladenosine. The new analog behaved as a competitive
inhibitor of Type III phosphodiesterase isolated from both guinea pig
and rat, although its Ki value was 10 times higher than that of milrinone. However, an increase in cAMP levels does
not seem to be involved in the mechanism of action of the new compound,
because the presence of carbachol did not decrease the extent of the
positive inotropic effect of the analog and did not modify its
EC50 in either guinea pig or rat myocardial preparations.
Taken together, these results suggest that the milrinone structure can
be modified, giving rise to a more active compound whose inotropic
effect in both guinea pig and rat appears to be more clearly related to
antagonism toward endogenous adenosine than to Type III
phosphodiesterase inhibition.